American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 796-803, May 2009

Uric Acid and Long-term Outcomes in CKD

  • Magdalena Madero, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
  • ,
  • Mark J. Sarnak, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA
  • ,
  • Xuelei Wang, MS

      Affiliations

    • Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, OH
  • ,
  • Tom Greene, PhD

      Affiliations

    • Division of Clinical Epidemiology, University of Utah, Salt Lake City, UT
  • ,
  • Gerald J. Beck, PhD

      Affiliations

    • Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, OH
  • ,
  • John W. Kusek, PhD

      Affiliations

    • National Institutes of Health, Bethesda, MD
  • ,
  • Allan J. Collins, MD

      Affiliations

    • Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN
  • ,
  • Andrew S. Levey, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA
  • ,
  • Vandana Menon, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA
    • Corresponding Author InformationAddress correspondence to Vandana Menon, MD, Division of Nephrology, Tufts Medical Center, Box 391, 800 Washington St, Boston, MA 02111

Received 15 October 2008; accepted 29 December 2008. published online 23 March 2009.

Background

Hyperuricemia is prevalent in patients with chronic kidney disease (CKD); however, data are limited about the relationship of uric acid levels with long-term outcomes in this patient population.

Study Design

Cohort study.

Setting & Participants

The Modification of Diet in Renal Disease (MDRD) Study was a randomized controlled trial (N = 840) conducted from 1989 to 1993 to examine the effects of strict blood pressure control and dietary protein restriction on progression of stages 3 to 4 CKD. This analysis included 838 patients.

Predictor

Uric acid level.

Outcomes & Measurements

The study evaluated the association of baseline uric acid levels with all-cause mortality, cardiovascular disease (CVD) mortality, and kidney failure.

Results

Mean age was 52 ± 12 (SD) years, glomerular filtration rate was 33 ± 12 mL/min/1.73 m2, and uric acid level was 7.63 ± 1.66 mg/dL. During a median follow-up of 10 years, 208 (25%) participants died of any cause, 127 (15%) died of CVD, and 553 (66%) reached kidney failure. In multivariate models, the highest tertile of uric acid was associated with increased risk of all-cause mortality (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.07 to 2.32), a trend toward CVD mortality (HR, 1.47; 95% CI, 0.90 to 2.39), and no association with kidney failure (HR, 1.20; 95% CI, 0.95 to 1.51) compared with the lowest tertile. In continuous analyses, a 1-mg/dL greater uric acid level was associated with 17% increased risk of all-cause mortality (HR, 1.17; 95% CI, 1.05 to 1.30) and 16% increased risk of CVD mortality (HR, 1.16; 95% CI, 1.01 to 1.33), but was not associated with kidney failure (HR, 1.02; 95% CI, 0.97 to 1.07).

Limitations

Primary analyses were based on a single measurement of uric acid. Results are generalizable primarily to relatively young white patients with predominantly nondiabetic CKD.

Conclusions

In patients with stages 3 to 4 CKD, hyperuricemia appears to be an independent risk factor for all-cause and CVD mortality, but not kidney failure.

Index Words: Kidney disease, uric acid, outcomes, cardiovascular, mortality, kidney failure

 

 Originally published online as doi:10.1053/j.ajkd.2008.12.021 on March 23, 2009.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Peter McCullough, MD, MPH, William Beaumont Hospital) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00077-8

doi:10.1053/j.ajkd.2008.12.021

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 796-803, May 2009